Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.

OBJECTIVE To compare liraglutide versus common antihyperglycemic treatments in reducing hemoglobin A1c (A1C) values across multiple levels of baseline glycemic control and in reaching glycemic targets. METHODS Pooled patient data from 7 phase 3, multinational, randomized controlled trials in patients with type 2 diabetes were stratified by baseline A1C values into 5 categories: ≤7.5%, >7.5% to 8.0%, >8.0% to 8.5%, >8.5% to 9.0%, and y9.0%. The changes in A1C from baseline to week 26 of treatment and patient proportions reaching A1C targets of <7.0% and ≤6.5% were compared between liraglutide (1.8 mg daily) and sitagliptin, glimepiride, rosiglit-azone, exenatide, and insulin glargine across all baseline A1C categories. RESULTS Irrespective of treatment, reductions in A1C levels were generally greater in groups with higher baseline A1C values. After 26 weeks of treatment, liraglutide produced the greatest reductions in A1C values across all baseline categories, ranging from 0.7% to 1.8% (baseline A1C categories ≤7.5% to >9.0%, respectively), followed by insulin glargine (0.3% to 1.5%) and then by glimepiride (0.4% to 1.3%). Generally, larger percentages of patients achieved the A1C target of ≤6.5% with liraglutide therapy across all baseline categories (from 62% of patients with A1C values ≤7.5% to 10% of patients with A1C values >9.0%) in comparison with other treatments (ranging from 49% to 0% of patients, respectively). Similarly, greater proportions of patients also reached the A1C target of <7.0% with liraglutide therapy across all baseline categories (from 83% of patients with A1C values ≤7.5% to 25% of patients with A1C values >9.0%) versus comparators (from 74% to 5% of patients, respectively). CONCLUSION Across a wide spectrum of baseline A1C categories, liraglutide is an efficacious treatment option for patients with type 2 diabetes.

[1]  B. Zinman,et al.  Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) , 2009, Diabetes Care.

[2]  R. Heine,et al.  Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes , 2005, Annals of Internal Medicine.

[3]  Dennis D. Kim,et al.  The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes , 2007, Annals of Internal Medicine.

[4]  B. Bode,et al.  Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial , 2009, The Lancet.

[5]  S. Colagiuri,et al.  Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[6]  K. Shojania,et al.  Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. , 2006, JAMA.

[7]  L. Blonde,et al.  The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies , 2009, Diabetes, obesity & metabolism.

[8]  A. Vaag,et al.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial , 2009, Diabetologia.

[9]  R. DeFronzo,et al.  Relationship of baseline HbA1c and efficacy of current glucose‐lowering therapies: a meta‐analysis of randomized clinical trials , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[10]  B. Goldstein,et al.  Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control? , 2003, Current medical research and opinion.

[11]  H. Gerstein,et al.  The Effect of Oral Antidiabetic Agents on A1C Levels , 2010, Diabetes Care.

[12]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[13]  D. Matthews,et al.  Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes , 2008, Diabetes Care.

[14]  D. Yin,et al.  Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA1c:a meta-analysis of published randomized clinical trials , 2006, Current medical research and opinion.

[15]  C. Viscoli,et al.  Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy , 2006, Diabetes Care.

[16]  R. Cuddihy,et al.  Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial , 2010, The Lancet.

[17]  M. Davies,et al.  Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. , 2005, Diabetes care.